Talking With Your Patients About Excessive Sweating

Slides:



Advertisements
Similar presentations
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Advertisements

Immunotherapies: Key Considerations in the Identification and Management of irAEs.
Systemic Lupus Erythematosus
New Psoriasis Treatments
T-Cell Exhaustion: Can We Overcome It in Cancer?
Advances in Managing Inhibitors in Patients With Hemophilia A
Updates on Emerging GLP-1 Receptor Agonists
Progression After Cancer Immunotherapy in Advanced NSCLC
Chronic Rhinosinusitis
Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update
New Standards of Care in ALK-Translocated Advanced NSCLC
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Navigating the Data and Evolving Our Approach
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Addressing Disease Burden in Asthma
Optimizing Management of Advanced Bladder Cancer
Multidisciplinary Perspectives on Interstitial Lung Diseases
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Management of CMV in HSCT Recipients
Evaluating Next-Generation BTK Inhibitors
Case Studies in Unresectable Hepatocellular Carcinoma
Hyperhidrosis Is Burdensome!
Therapeutic Approaches to the Management of EDS in OSA
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Ask the Experts.
Immunotherapy for cSCC
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
New Data on Emerging Treatments for Psoriasis
When Is Biologic Therapy Appropriate for HS?
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Personalizing Management in the Care of Patients With Advanced Sarcoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Developments in the Wet AMD Treatment Landscape
Parkinson Disease Psychosis
Prophylaxis Strategies in Hereditary Angioedema Weighing the Evidence
Advances in Immunotherapy for Peanut Allergy
Immune Checkpoint Inhibitors in Lung Cancer
Guide to Atopic Dermatitis
Current Issues and Emerging Advances in the Management of PKU
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Expanding the Horizons in Hereditary Angioedema
EGPA.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient Questions and Expert Answers in Psoriasis:
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
The Psychiatrist's Role in Tardive Dyskinesia
Patient and Clinician Perspectives on Preventive Therapy for Migraine
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Novel Concepts in the Management of RCC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
From Adjuvant to Metastatic in Melanoma
Why New Treatments for Hyperhidrosis Should Be on Your Radar
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Psychiatrist's Role in Tardive Dyskinesia
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
VKA Reversal and LVADs.
How to Select Therapy in Relapsed/Refractory CLL
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Presentation transcript:

Talking With Your Patients About Excessive Sweating

This program will include a discussion of off-label treatment, devices, and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

How to Approach Patients with Hyperhidrosis

Acknowledge the Medical Condition

Effects Begin in Childhood and Adolescence

Initiate the Conversation Validation and Education

Establish the Diagnosis

Diagnostic Criteria Primary Focal Hyperhidrosis

Treatment Option Overview for HH

Iontophoresis and MTS

Emerging Treatments

When Palmar HH Is An Occupational Hazard: Patient Case Examples

Elevate Shared Decision-Making

Staff Contributes to Improved Patient Care

Be a 'Medical Home' for Patients

Endoscopic Thoracic Sympathectomy

Roles of Healthcare Providers

Role of School Nurses

Considerations

Considerations

Concluding Remarks

Abbreviations